APP-NEA

Sleep Apnea affects more than 20% of the population but less than 20% are diagnosed. It is associated with several chronic medical conditions and increase in health care costs. Under-diagnosis is mainly due to low awareness among GPs and long waiting times to perform compulsory exams.

In parallel to diagnosis innovation, there is a need to enlarge screening. Primary care is in the best position to identify Sleep Apnea patients with symptoms, but implementation is still a challenge.

Sleep Apnea and Apneal app

Apneal relies on the patient’s smartphone: no training, no investment nor logistics required, all conditions that greatly simplify the workflow, making it possible at the GP’s. Based on AI, Apneal initial results shows great performance, even comparable to diagnosis standards.

With the APP-NEA consortium, we ambition to:

• Validating Apneal capacity to deeply transform Sleep Apnea diagnosis and treatment access
• Fast track the reimbursement process of the Medical Device
• Deploy the solution in Europe

APP-NEA consortium

• Air Liquide Santé International, France
• Biomedic Research Foundation Getafe's Hospital, Spain
• DIGITAL MEDICAL HUB, France
• Ethik-IA, France
• Fundación para la Investigación Biomédica del Hospital 12 de Octubre, Spain
• Group ProductLife, France
• Institut National de la Sante et de la Recherche Médicale (INSERM), France
• MADoPA - Centre Expert en Technologies et Services pour le Maintien en Autonomie à Domicile des Personnes Agées, France
• Metropolia University of Applied Sciences / Health Proof, Finland
• Mitral - Apneal, France
• Servicio Madrileño de Salud (SERMAS), Spain

Visit Apneal website (in French).

Metropolia contact information

Jarmo Tuppurainen
Technology Manager
jarmo.tuppurainen [at] metropolia.fi (jarmo[dot]tuppurainen[at]metropolia[dot]fi)